Trending...
- Independent Global Film Movement Tackles Diversity Issues At The 75th Festival De Cannes
- ONE Brands & FULFIL™ Join Forces at TheFitExpo Los Angeles
- Planful Announces Availability of Predict: Projections and Enhancements to the Business User Experience, Extending Its Planning and Budgeting Innovations
SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) securities between June 1, 2021 and November 4, 2021, for violations of the Securities Exchange Act of 1934. NRx is a clinical-stage pharmaceutical company that develops therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The Company's products include, among others, ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure.
If you suffered a loss due to NRx Pharmaceuticals, Inc.'s misconduct, click here.
More on The Californer
NRx Pharmaceutical, Inc. (NRXP) Misled Investors Regarding the EAU Status of its Drug Candidate
According to the complaint, in June 2021, NRx announced it had filed an application with the U.S. Food and Drug Administration ("FDA") requesting Emergency Use Authorization ("EUA") for ZYESAMI to treat critically ill COVID-19 patients suffering with respiratory failure. However, defendants failed to disclose that the ZYESAMI EUA application contained insufficient data regarding the potential benefits and risks of the drug and therefore, the FDA was unlikely to approve the ZYESAMI EUA application in its present form.
On November 4, 2021, NRx issued a press release announc[ing] that the [FDA] has declined to issue an [EUA] for ZYESAMI® (aviptadil). The FDA stated that it was unable to issue the EUA at this time due to insufficient data regarding the known and potential benefits of the medicine and the known and potential risks of ZYESAMI in patients suffering from Critical COVID-19 with respiratory failure." On this news, NRx's stock price fell $2.27 per share or over 25%, to close at $6.65 per share on November 5, 2021.
If you purchased shares of NRx Pharmaceutical, Inc. (NRXP) between June 1, 2021 and November 4, 2021, you have until March 21, 2022, to ask the court to appoint you lead plaintiff for the class.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
More on The Californer
Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against NRx Pharmaceutical, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Contacts
Aaron Dumas
Robbins LLP
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com
If you suffered a loss due to NRx Pharmaceuticals, Inc.'s misconduct, click here.
More on The Californer
- Trepont Acquisition Corp I Announces Redemption of Class A Ordinary Shares
- Fantastic Sams Franchise Corporation Partners with First Development Agent in the Brand's Ambitious Expansion Initiative
- Cabrillo EDC Empowers Ventura County Residents for Success during NeighborWorks Week
- San Jose: Affordable Housing Project Gets $54.8M from State
- Brian Peterson assisted Kaplan Tarps & Cargo Controls with obtaining a GSA Multiple Award Schedule
NRx Pharmaceutical, Inc. (NRXP) Misled Investors Regarding the EAU Status of its Drug Candidate
According to the complaint, in June 2021, NRx announced it had filed an application with the U.S. Food and Drug Administration ("FDA") requesting Emergency Use Authorization ("EUA") for ZYESAMI to treat critically ill COVID-19 patients suffering with respiratory failure. However, defendants failed to disclose that the ZYESAMI EUA application contained insufficient data regarding the potential benefits and risks of the drug and therefore, the FDA was unlikely to approve the ZYESAMI EUA application in its present form.
On November 4, 2021, NRx issued a press release announc[ing] that the [FDA] has declined to issue an [EUA] for ZYESAMI® (aviptadil). The FDA stated that it was unable to issue the EUA at this time due to insufficient data regarding the known and potential benefits of the medicine and the known and potential risks of ZYESAMI in patients suffering from Critical COVID-19 with respiratory failure." On this news, NRx's stock price fell $2.27 per share or over 25%, to close at $6.65 per share on November 5, 2021.
If you purchased shares of NRx Pharmaceutical, Inc. (NRXP) between June 1, 2021 and November 4, 2021, you have until March 21, 2022, to ask the court to appoint you lead plaintiff for the class.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
More on The Californer
- Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022
- RH to Report First Quarter Fiscal 2022 Financial Results on June 2, 2022
- California Distributes $108.6 Million to Create Regional Education-to-Career Pipelines
- San Francisco: Mayor London Breed Announces $50.7 Million Investment Over Two Years in Children and Family Recovery Plan in Proposed Budget
- Enry's Island Set to be the First Incubator-Accelerator to Have its Own Building in a Metaverse
Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against NRx Pharmaceutical, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Contacts
Aaron Dumas
Robbins LLP
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com
Filed Under: Business
0 Comments
Latest on The Californer
- Armorblox Email Security Threat Report Reveals Huge Uptick in Language-Based Business Email Compromise Attacks
- GoodLoan.io provides update on current mortgage interest rates
- California Senate Votes to Support CARE Court, as Leading State Business Organizations Join Expanding Coalition
- CORRECTING and REPLACING CAPTION BSI Wins Best Biotech Startup Business of the Year 2022 Award
- Wigs to Create the Perfect Hairstyle for Graduation Season Are Coming
- Jessica Ross Graces the Cover of Center Stage Magazine
- PEGA Investor Alert: Robbins LLP Remind Shareholders of Class Action Against Pegasystems Inc. (PEGA)
- All-optical computation of a group of transformations using polarization-encoded diffractive network
- California: Following Texas Elementary School Shooting, Governor Newsom and Legislative Leaders to Expedite Gun Reform Legislation
- San Jose: : New Deputy City Manager to Tackle Homelessness and Quality of Life Challenges
- Long Beach: A Message on the Tragedy in Texas
- Momentus Launches First Demonstration Flight on SpaceX Falcon 9
- Harmonic to Participate in the Jefferies Software Conference
- Rising to the Challenge of the Human Experience
- San Jose: San José Affordable Housing Development Awarded $54.8 million from State
- Multi-Billion Dollar Wellness Industry is Fatally Flawed and You're Paying the Price: Here's What You Need to Know
- Up and coming POP / R&B Girl Group Releases New Music Video
- American Vanguard Calls on Cruiser Capital to Be Fully Transparent With Stockholders
- Attention All Kinds of Businesses: Is your Advertising Producing the Results you were Hoping for?
- DB Capital Acquires Denver Metro Apartment Community for $38 Million